「NMDA」の共起表現(1語左で並び替え) - Weblio英語共起表現検索

Weblio 辞書 > 英和辞典・和英辞典 > NMDAの意味・解説 > NMDAに関連した共起表現

意味

例文

共起表現

「NMDA」の共起表現一覧(1語左で並び替え)

該当件数 : 93件

Huperzine A is also a	NMDA receptor antagonist which protects the brain ag
as a neuronal signaling molecule by activating	NMDA receptors in the brain.
sions") occurred in brains of rats administered	NMDA antagonists, including PCP, MK-801 (dizocilpine
decahydroquinoline (8A-PDHQ) is a high affinity	NMDA antagonist.
It also acts as an	NMDA receptor antagonist.
estinel (GV-150,526) is a drug which acts as an	NMDA antagonist, binding selectively to the glycine
esthetic and pharmacologically classified as an	NMDA receptor antagonist.
esonprodil (CI-1041) is a drug which acts as an	NMDA antagonist, selective for the NR2B subunit.
iprodil (SL-82.0715) is a drug which acts as an	NMDA antagonist, binding to the polyamine modulatory
elucemine (NPS-1506) is a drug which acts as an	NMDA antagonist and a serotonin reuptake inhibitor,
s a drug related to memantine, which acts as an	NMDA antagonist and has neuroprotective effects.
It acts as an	NMDA receptor antagonist but has low potency and act
is a drug developed by Pfizer which acts as an	NMDA antagonist, selective for the NR2B subunit.
As an	NMDA receptor antagonist, in vivo, it is approximate
nervous system and has its mode of action as an	NMDA receptor antagonist.
ome apparent 2 hours after administration of an	NMDA antagonist.
tive than 18-MC with very little activity as an	NMDA antagonist and only slight affinity for the del
eceptor agonist, κ-opioid receptor agonist, and	NMDA receptor antagonist.
ated ion channels and include AMPA, Kainate and	NMDA.
ls and has a low affinity for AMPA, kainate and	NMDA receptors.
ol's acute effects on GABAergic enhancement and	NMDA suppression, leading to CNS depression leading
A and 5-HT2C), 5-HT6, 5-HT7, α1-adrenergic, and	NMDA receptors, and as agonists at the sigma recepto
ors it has been demonstrated to function on are	NMDA and the D1 dopamine receptor.
oxic changes corresponded with their potency as	NMDA antagonists: i.e.
ther ionotropic receptors for glutamate such as	NMDA and AMPA.
neurotrophic factor (BDNF), glutamate acting at	NMDA receptors, dopamine through activation of the D
zoline I2 receptor antagonists reversibly block	NMDA receptor-mediated Ca2+ influx and thus may inhi
ing within in vitro preparations, and can block	NMDA receptor action at a reasonably small concentra
eptor and imidazoline binding sites, and blocks	NMDA receptors and other cation ligand-gated channel
trorotary isomer, dextromethorphan, is a common	NMDA receptor antagonist and pro-drug to dextrorphan
GS-19755) is a drug which acts as a competitive	NMDA antagonist, directly competing with glutamate f
and that the cortical	NMDA receptor properties and membrane fluidity are a
rent ability to stabilize disrupted or disabled	NMDA receptor pathways in the brain, which are share
I added dissociatives (	NMDA antagonists) as psychedelics.
ensory nerve terminals in the skin also express	NMDA and non-NMDA receptors.
ying ovarian or mediastinal teratoma expressing	NMDA receptors.
ty of several ion channels including the GABAA,	NMDA, and sigma receptors.
Glutamate [	NMDA] receptor subunit 3A is a protein that in human
Glutamate [	NMDA] receptor subunit epsilon-1 is a protein that i
Glutamate [	NMDA] receptor subunit epsilon-4 is a protein that i
Glutamate [	NMDA] receptor subunit 3B is a protein that in human
") and ketamine, both of which block glutamate (	NMDA) receptors, are known to cause psychosis closel
Dextrorphan - A dissociative hallucinogen (	NMDA receptor antagonist) and cough suppressant.
.3x meperidine in potency) although it also has	NMDA antagonist properties like its close relative k
ulators of a variety of ion channels, including	NMDA receptors and AMPA receptors.
apse to an active one, since this conversion is	NMDA receptor-dependent.
Its	NMDA actions, similar to those of the phenylheptylam
Lacosamide does not affect AMPA, kainate,	NMDA, GABAA, GABAB or a variety of dopaminergic, ser
It has also been shown to act as a low-affinity	NMDA receptor antagonist.
-physiological partial agonist of the mammalian	NMDA receptor.
In animal models,	NMDA antagonists increase glutamate release in the p
development of synaptic elements by modulating	NMDA receptor activity.
Most	NMDA receptor antagonists are metabolized in the liv
Frequent administration of most	NMDA receptor antagonists can lead to tolerance, whe
N-methyl-D-aspartate (	NMDA) receptors are a class of ionotropic glutamate
ith different subunits of N-methyl-D-aspartate (	NMDA) receptor.
encodes a subunit of the N-methyl-D-aspartate (	NMDA) receptors, which belong to the superfamily of
It is a non-competitive	NMDA antagonist and calcium channel blocker
e AMPA receptor antagonist, and non-competitive	NMDA receptor antagonist.
ts and instead acts as a potent non-competitive	NMDA antagonist.
-1102) is a drug which acts as a noncompetitive	NMDA antagonist.
able AMPA receptor and kainate receptor but not	NMDA receptor.
d her colleagues demonstrated the importance of	NMDA receptors in development plasticity.
The induction of	NMDA receptor-dependent long-term potentiation (LTP)
A class of	NMDA receptor antagonists have been denoted dissocia
holine antagonists, with little or no effect on	NMDA receptors.
Glutamate opens	NMDA receptors on other neurons which allows calcium
MK-801, along with other	NMDA antagonists, induce the formation of brain lesi
Other	NMDA receptor modulators are being studied and this
otel (EAA-090) is a drug which acts as a potent	NMDA antagonist.
de of GlyT1 has been hypothesized to potentiate	NMDA receptor function in vivo and to represent a ra
(Tet-Gly, LY-285,265) is a potent and selective	NMDA receptor agonist, stimulating the NMDA receptor
2R)-amino-5-phosphonopentanoate) is a selective	NMDA receptor antagonist that competitively inhibits
AP-7 is a selective	NMDA receptor (NMDAR) antagonist that competitively
CKA (5,7-dichlorokynurenic acid) is a selective	NMDA receptor (NMDAR) antagonist acting at the glyci
ffects on Aplysia long-term potentiation, since	NMDA receptors are required for both.
r treatment focus because glutamate blocks some	NMDA receptors which, on their own, induce schizophr
l experiments, Palazzo et al. demonstrated that	NMDA, an ionotropic glutamate receptor, and the meta
PEAQX is a competitive antagonist at the	NMDA receptor.
Chemicals that deactivate the	NMDA receptor are called antagonists.
should be drafted for the establishment of the	NMDA.
Examples include haemoglobin (pictured), the	NMDA receptor, some aquaporins, some AMPA receptors,
dies of glycine (and related co-agonists at the	NMDA receptor) added to conventional anti-psychotics
an receptor site is the PCP binding site in the	NMDA receptor, a type of ligand-gated ion channel.
antibodies to the delta2 or NR2 subunits of the	NMDA receptor.
kappa and delta opioid, sigma receptors, or the	NMDA system are not well understood.
red in combination with other drugs such as the	NMDA antagonist tiletamine or the alpha-2 adrenergic
After repeated doses of the	NMDA antagonists MK-801 and PCP, the vacuolation rea
stulated that this is a homeostatic response to	NMDA receptor blockade, which in turn increases psyc
as increased glucose metabolism in response to	NMDA antagonist exposure.
t a hypofunction of glutamatergic signaling via	NMDA receptors.
a number of receptor systems, being both a weak	NMDA antagonist and a 5HT1A agonist.
antidepressant effect when co-administered with	NMDA antagonists.

共起表現